Literature DB >> 32156524

Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease.

Ze Chen1, Ruifeng Tian1, Zhigang She2, Jingjing Cai3, Hongliang Li4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease worldwide and is strongly associated with the presence of oxidative stress. Disturbances in lipid metabolism lead to hepatic lipid accumulation, which affects different reactive oxygen species (ROS) generators, including mitochondria, endoplasmic reticulum, and NADPH oxidase. Mitochondrial function adapts to NAFLD mainly through the downregulation of the electron transport chain (ETC) and the preserved or enhanced capacity of mitochondrial fatty acid oxidation, which stimulates ROS overproduction within different ETC components upstream of cytochrome c oxidase. However, non-ETC sources of ROS, in particular, fatty acid β-oxidation, appear to produce more ROS in hepatic metabolic diseases. Endoplasmic reticulum stress and NADPH oxidase alterations are also associated with NAFLD, but the degree of their contribution to oxidative stress in NAFLD remains unclear. Increased ROS generation induces changes in insulin sensitivity and in the expression and activity of key enzymes involved in lipid metabolism. Moreover, the interaction between redox signaling and innate immune signaling forms a complex network that regulates inflammatory responses. Based on the mechanistic view described above, this review summarizes the mechanisms that may account for the excessive production of ROS, the potential mechanistic roles of ROS that drive NAFLD progression, and therapeutic interventions that are related to oxidative stress.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endoplasmic reticulum stress; Innate immunity; Insulin resistance; Lipid metabolism; Mitochondrial dysfunction; Nonalcoholic fatty liver disease; Oxidative stress

Mesh:

Substances:

Year:  2020        PMID: 32156524     DOI: 10.1016/j.freeradbiomed.2020.02.025

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  124 in total

1.  Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Suguru Ikeda; Takaaki Sugihara; Yoshiki Hoshino; Yukako Matsuki; Takakazu Nagahara; Jun-Ichi Okano; Sonoko Kitao; Youhei Fujioka; Kazuhiro Yamamoto; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2020-08-07       Impact factor: 1.641

2.  Reduction of Hepatic Steatosis, Oxidative Stress, Inflammation, Ballooning and Insulin Resistance After Therapy with Safranal in NAFLD Animal Model: A New Approach.

Authors:  Usman Sabir; Hafiz Muhammad Irfan; Aman Ullah; Yusuf S Althobaiti; Mulazim Hussain Asim
Journal:  J Inflamm Res       Date:  2022-02-24

Review 3.  The Impact of H2S on Obesity-Associated Metabolic Disturbances.

Authors:  Ferran Comas; José María Moreno-Navarrete
Journal:  Antioxidants (Basel)       Date:  2021-04-21

4.  Phenolic Compounds from Carissa spinarum Are Characterized by Their Antioxidant, Anti-Inflammatory and Hepatoprotective Activities.

Authors:  Ye Liu; Yongli Zhang; Felix Wambua Muema; Festus Kimutai; Guilin Chen; Mingquan Guo
Journal:  Antioxidants (Basel)       Date:  2021-04-23

5.  Hyoscyamus albus nortropane alkaloids reduce hyperglycemia and hyperinsulinemia induced in HepG2 cells through the regulation of SIRT1/NF-kB/JNK pathway.

Authors:  Anna Kowalczuk; Nabila Bourebaba; Katarzyna Kornicka-Garbowska; Eliza Turlej; Krzysztof Marycz; Lynda Bourebaba
Journal:  Cell Commun Signal       Date:  2021-05-25       Impact factor: 5.712

Review 6.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 7.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

8.  Liver proteome alterations in psychologically distressed rats and a nootropic drug.

Authors:  Raquel González-Fernández; Mariana Grigoruţă; Sarahi Chávez-Martínez; Eliel Ruiz-May; José Miguel Elizalde-Contreras; José Valero-Galván; Alejandro Martínez-Martínez
Journal:  PeerJ       Date:  2021-05-19       Impact factor: 2.984

Review 9.  The Role of Cellular Stress in Intrauterine Growth Restriction and Postnatal Dysmetabolism.

Authors:  Shelby L Oke; Daniel B Hardy
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 10.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.